Press Release
Press Release
Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline
Read Full Story
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Business
Press Release
Press Release
Press Release
Press Release
Press Release